The CSIC has developed an immunotherapy approach based on a bifunctional compound for the treatment and prevention of prostate cancer, the second most common cancer worldwide for men and fifth most common cancer overall. Industrial partners from the pharmaceutical industry are being sought, for collaboration through a patent licence agreement.